Cancer subtypes are rarely captured in structured EMR data but are important for clinical outcomes and cost analyses. ConcertAI developed an AI model to identify NSCLC patients from a heterogeneous cohort of lung cancer patients.
Few clinical characteristics of patient with exceptional response to existing cancer therapies are known. ConcertAI trained a deep learning model to predict slow progression, a proxy, in aNSCLC in the second line setting.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.